Advertisement

The Discovery of Angiogenesis Factors

  • Domenico Ribatti
Chapter

Abstract

Until the early 1970s it was widely assumed that tumors did not produce specific angiogenic proteins. The conventional widsom was that tumor vasculature was an inflammatory reaction to dying or necrotic tumor cells. Previous studies had shown that tumor-stimulated vessel growth did not require direct contact between tumor and host tissue (Greenblatt and Shubik 1968; Ehrman and Knoth 1968). This made sense to Folkman, who reasoned that a soluble factor would be more likely to reach nearly than distant blood vessels. He and his colleagues isolated an angiogenic factor in 1971 (Folkman et al. 1971). The homogenate of a Walker 256 carcinoma – a breast tumour of Sprague-Dawley rats – was fractionated by gel-filtration on Sephadex G-100. The fraction that exhibited the strongest angiogenic activity had a molecular weight of about 10,000 daltons and consisted of 25% RNA, 10% proteins, and 58% carbohydrates, plus a possible lipid residue that appeared to be protective. It was inactivated by digestion with pancreatic ribonuclease, or by heating at 56 °C for 1 h, and was not modified when kept at 4 °C for 3 months, nor when treated with trypsin for more than 3 days. This active fraction was subsequently called “tumour angiogenesis factor” (TAF) (Folkman et al. 1971). Histone and non-histone fractions were separated by CM sephadex chromatography. The histone fraction showed no activity but the non-histone proteins contained strong angiogenic activity (Tuan et al. 1973). Both the cytoplasmic and the nuclear fractions of tumor cells stimulated angiogenesis. In the nuclear fraction, this was found to be associated with non-histonic proteins (Tuan et al. 1973). TAF has since been non-destructively extracted from several tumor cell lines, and several low molecular weight angiogenic factors have been isolated, again from the Walker 256 carcinoma. These factors induced a vasoproliferative response in vivo when tested on rabbit cornea or chick CAM, and in vitro on cultured endothelial cells (Mc Auslan and Hoffman 1979; Weiss et al. 1979; Fenselau et al. 1981).

References

  1. Achen MG, McColl BK, Stacker SA (2005) Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 7:121–127CrossRefPubMedGoogle Scholar
  2. Brown LF, Van DeWater L, Harvey VS et al (1988) Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol 130:455–465PubMedPubMedCentralGoogle Scholar
  3. Carmeliet P, Ferrerira V, Breier G et al (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435–443CrossRefPubMedPubMedCentralGoogle Scholar
  4. Collins PD, Connolly DT, Williams TJ (1993) Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br J Pharmacol 109:195–199CrossRefPubMedPubMedCentralGoogle Scholar
  5. Connolly DT, Heuvelman DM, Nelson R et al (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470–1478CrossRefPubMedPubMedCentralGoogle Scholar
  6. Dvorak HF (1986) Tumors: wounds that not heal. Similarities between tumor stroma generation and wound healing. New Engl J Med 315:1650–1659CrossRefPubMedGoogle Scholar
  7. Dvorak HF, Orenstein NS, Carvalho A et al (1979) Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 122:166–174PubMedGoogle Scholar
  8. Dvorak HF, Dickersin GR, Dvorak AM et al (1981) Human breast carcinoma: Fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. J Nat Cancer Inst 67:337–345Google Scholar
  9. Dvorak HF, Senger DR, Dvorak AM (1983) Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 2:41–73CrossRefPubMedGoogle Scholar
  10. Dvorak HF, Harvey VS, McDonagh J (1984) Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. Cancer Res 44:3348–3354PubMedGoogle Scholar
  11. Dvorak HF, Nagy JA, Berse B et al (1992) Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci 667:101–111CrossRefPubMedGoogle Scholar
  12. Dvorak HF, Brown LF, Detmar M et al (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039PubMedPubMedCentralGoogle Scholar
  13. Ehrman RL, Knoth M (1968) Choriocarcinoma: transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. J Natl Cancer Inst 41:1329–1341Google Scholar
  14. Esch F, Baird A, Ling N et al (1985) Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci U S A 82:6507–6511CrossRefPubMedPubMedCentralGoogle Scholar
  15. Fenselau A, Kaiser D, Wallis K (1981) Nucleoside requirements for the in vivo growth of bovine aortic endothelial cells. J Cell Physiol 108:375–384CrossRefPubMedGoogle Scholar
  16. Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851–858CrossRefPubMedGoogle Scholar
  17. Ferrara N, Carver Moore K, Chen H et al (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439–442CrossRefPubMedPubMedCentralGoogle Scholar
  18. Folkman J (1971) Tumor angiogenesis. Therapeutic implications. N Engl J Med 285:1182–1186CrossRefPubMedPubMedCentralGoogle Scholar
  19. Folkman J (1985a) Toward an understanding of angiogenesis: search and discovery. Perspect Biol Med 29:10–36CrossRefPubMedGoogle Scholar
  20. Folkman J (1985b) Tumor angiogenesis. Adv Cancer Res 43:175–203CrossRefPubMedGoogle Scholar
  21. Folkman J (2008) Tumor angiogenesis: from bench to bedside. In: Marmé D, Fusenig N (eds) Tumor angiogenesis. Basic mechanisms nad cancer therapy. Springer-Verlag, Heidelberg, pp 3–28Google Scholar
  22. Folkman J, Merler E, Abernathy C et al (1971) Isolation of a tumor fraction responsible for angiogenesis. J Exp Med 133:275–288CrossRefPubMedPubMedCentralGoogle Scholar
  23. Gospodarowicz D (1974) Localization of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 249:123–127CrossRefPubMedGoogle Scholar
  24. Greenblatt M, Shubik P (1968) Tumor angiogenesis: transfilter diffusion studied in the hamster by the transparent chamber technique. J Natl Cancer Inst 41:1111–1124Google Scholar
  25. Houck KA, Ferrara N, Winer J et al (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806–1814CrossRefPubMedGoogle Scholar
  26. Houck KA, Leung DW, Rowland AM et al (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031–26037PubMedGoogle Scholar
  27. Jeltsch M, Kaipanen A, Joukov V et al (1997) Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423–1425CrossRefGoogle Scholar
  28. Joukov V, Pajusola K, Kaipanen A et al (1996) A novel vascular endothelial growth factor, VEGF-C is a ligand for the l-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290–298PubMedPubMedCentralCrossRefGoogle Scholar
  29. Kaipanen A, Korhonen J, Mustonen T et al (1995) Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 92:3566–3570CrossRefGoogle Scholar
  30. Kech PJ, Hauser SD, Krivi G et al (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309–1312CrossRefGoogle Scholar
  31. Kim KJ, Li B, Winer J et al (1993) Isolation of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth. Nature 362:841–844CrossRefPubMedPubMedCentralGoogle Scholar
  32. Leung DW, Cachianes G, Kuang WJ et al (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309CrossRefGoogle Scholar
  33. Maglione D, Guerriero V, Viglietto G et al (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 88:9267–9271CrossRefPubMedPubMedCentralGoogle Scholar
  34. Mc Auslan BR, Hoffman H (1979) Endothelium stimulating factor from Walker carcinoma cells. Relation to tumor angiogenic factor. Exp Cell Res 119:181–190CrossRefGoogle Scholar
  35. Millauer B, Shawver LK, Plate KH et al (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576–579CrossRefPubMedGoogle Scholar
  36. Moscatelli D, Presta M, Rifkin DB (1986) Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proc Natl Acad Sci U S A 83:2091–2095CrossRefPubMedPubMedCentralGoogle Scholar
  37. Nagy JA, Masse EM, Herzberg KT et al (1995) Pathogenesis of ascites tumor growth. Vascular permeability factor, vascular hyperpermeability and ascites fluid accumulation. Cancer Res 55:360–368PubMedGoogle Scholar
  38. Presta M, Moscatelli D, Joseph-Silverstein J et al (1986) Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 6:4060–4066CrossRefPubMedPubMedCentralGoogle Scholar
  39. Presta LG, Chen H, O’Connor SJ et al (1997) Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599PubMedGoogle Scholar
  40. Ribatti D (2008) Napoleone Ferrara and the saga of vascular endothelial growth factor. Endothelium 15:1–8CrossRefPubMedGoogle Scholar
  41. Rosenthal RA, Megyesi JF, Henzel WJ et al (1990) Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors 4:53–59CrossRefPubMedGoogle Scholar
  42. Senger DR, Galli SJ, Dvorak AM et al (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985CrossRefPubMedGoogle Scholar
  43. Shing Y, Folkman J, Sullivan R et al (1984) Heparin affinity: purification of a tumor-dervied capillary endothelial cell growth factor. Science 223:1296–1299CrossRefPubMedGoogle Scholar
  44. Tuan D, Smith S, Folkman J et al (1973) Isolation of the nonhistone proteins of rat Walker 256 carcinoma. Their association with tumor angiogenesis. Biochemistry 12:3159–3165CrossRefPubMedGoogle Scholar
  45. Weiss JB, Brown RA, Kumar S et al (1979) An angiogenic factor isolated from tumours: a potent low-molecular weight compound. Brit J Cancer 40:493–496CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Domenico Ribatti
    • 1
  1. 1.Department of Basic Medical Sciences, Neurosciences and Sensory OrgansUniversity of Bari Medical SchoolBariItaly

Personalised recommendations